ASCO Welcomes 2015-2016 Board of Directors

Jun 28, 2015

ASCO is pleased to welcome the 2015–2016 ASCO Board of Directors and introduce seven newly instated leaders, who began their terms at the conclusion of the Annual Business Meeting during the 2015 ASCO Annual Meeting in Chicago.

Major priorities for the incoming Board will be the appropriate clinical use of genomic information and technologies; the development of CancerLinQ™ and other ASCO efforts to improve quality and value in cancer care; the global burden of cancer, particularly in areas with the most limited resources; the economics of oncology practice and health care payment reform; advocating for continued support of crucial medical research; and engaging every member of ASCO at each stage of their career.

BOARD OFFICERS

2015-2016 PRESIDENT
Julie M. Vose, MD, MBA, FASCO, is the Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/Hematology Division in the Department of Internal Medicine at the University of Nebraska Medical Center. She is the Associate Director of Clinical Research at the Fred and Pamela Buffett Cancer Center.

2015-2016 PRESIDENT-ELECT
Daniel F. Hayes, MD, FASCO, is a Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center.
 

IMMEDIATE PAST PRESIDENT
Peter Paul Yu, MD, FACP, FASCO, is a medical oncologist and hematologist and Director of Cancer Research at Palo Alto Medical Foundation, where he has worked since 1989.
 

TREASURER
Craig R. Nichols, MD, is the Co-Director of the Testicular Cancer Multidisciplinary Clinic at Virginia Mason Medical Center in Seattle. He serves as co-primary investigator on the recently funded Northwest National Cancer Institute Community Oncology Research Program. Dr. Nichols is the Executive Officer of Cancer Control and Prevention Research for the Southwest Oncology Group.

BOARD MEMBERS

PEDIATRIC ONCOLOGIST
Smita Bhatia, MD, MPH, is the Director of the Institute for Cancer Outcomes and Survivorship at the University of Alabama at Birmingham (UAB) School of Medicine, and the Vice Chair for Outcomes in the Department of Pediatrics and Associate Director for Cancer Outcomes Research at the UAB Comprehensive Cancer Center.

UNDESIGNATED SPECIALIST
Charles D. Blanke, MD, FACP, FASCO, is a Professor of Medicine in the Division of Hematology and Medical Oncology at Oregon Health and Science University’s Knight Cancer Institute.
 

COMMUNITY ONCOLOGIST
Linda Bosserman, MD, FACP, is an Assistant Clinical Professor and staff physician at City of Hope.

 

RADIATION ONCOLOGIST
Walter J. Curran, Jr., MD, FACR, is the Executive Director of the Winship Cancer Institute of Emory University, the Lawrence W. Davis Professor and Chair of Emory’s Department of Radiation Oncology, and the Associate Vice President for Cancer at the Woodruff Health Sciences Center.

UNDESIGNATED SPECIALIST
Stephen B. Edge, MD, FACS, FASCO, is the Director of the Baptist Cancer Center and an Adjunct Professor of Surgery at the Vanderbilt University School of Medicine.
 

UNDESIGNATED SPECIALIST
Paulo M. G. Hoff, MD, PhD, FACP, is a Professor of Oncology and General Director of the ICESP—Instituto do Câncer do Estado de São Paulo, at the University of São Paulo, and General Director of the Oncology Center at the Hospital Sírio Libanês, Brazil.

UNDESIGNATED SPECIALIST
Hagop M. Kantarjian, MD, is Department Chair, the Kelcie Margaret Kana Research Chair, a Professor in the Department of Leukemia, and Associate Vice President for Global Academic Programs at the University of Texas MD Anderson Cancer Center

INTERNATIONAL ONCOLOGIST
David Khayat, MD, PhD, FASCO, is the Head of the Department of Medical Oncology at Pitié- Salpêtrière Hospital, in Paris, France.
 

UNDESIGNATED SPECIALIST
Gary H. Lyman, MD, MPH, FACP, FRCP (Edin), FASCO, is Co- Director of the Hutchinson Institute for Cancer Outcomes Research, a Full Member of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, and a Professor of Medicine and Medical Oncology at the University of Washington.

MEDICAL ONCOLOGIST
Neal J. Meropol, MD, FASCO, is a Professor of Medicine and Chief of the Division of Hematology and Oncology at University Hospitals Case Medical Center & Case Western Reserve University, Associate Director for Clinical Research at Case Comprehensive Cancer Center, Associate Director for Clinical Programs at University Hospitals Seidman Cancer Center, and the Dr. Lester E. Coleman, Jr., Endowed Chair in Cancer Research and Therapeutics.

COMMUNITY ONCOLOGIST
Therese M. Mulvey, MD, FASCO, is the Physicianin- Chief at Southcoast Centers for Cancer Care, Massachusetts.

 

COMMUNITY ONCOLOGIST
J. Chris Nunnink, MD, FASCO, is an Attending Physician in Medical Oncology at the University of Vermont Medical Center and an Associate Professor at the Vermont Cancer Center and the College of Medicine at the University of Vermont.

CONQUER CANCER FOUNDATION BOARD OF DIRECTORS CHAIR
W. Charles Penley, MD, FASCO, is a partner with Tennessee Oncology, PLLC, and has been treating patients in community practice for more than 25 years.
 

INTERNATIONAL ONCOLOGIST
Lillian L. Siu, MD, FRCPC, is a senior medical oncologist at Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto. She directs the Phase I Program and the Cancer Genomics Program and is the clinical leader for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre.

UNDESIGNATED SPECIALIST
Jedd D. Wolchok, MD, PhD, is Chief of the Melanoma and Immunotherapeutics Service in the Department of Medicine and the Associate Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.

Back to Top